Human resistin and the RELM of Inflammation in diabesity

Diabetology & Metabolic Syndrome

Kevin Gerard Culligan¹  Fatima Al Hannan² 

[1] Royal College of Surgeons in Ireland – Bahrain, Adliya, Kingdom of Bahrain;Department of Biomedical Sciences, Royal College of Surgeons in Ireland – Bahrain, Building No. 2441, Road 2835, Busaiteen, Kingdom of Bahrain

关键词: RELMβ;    Resistin;    Inflammation;    Diabetes;    Obesity;    Diabesity;   

Others  :  1220760
DOI  :  10.1186/s13098-015-0050-3

 received in 2015-02-20, accepted in 2015-06-05,  发布年份 2015

【 摘 要 】

The initial discovery of resistin and resistin-like molecules (RELMs) in rodents suggested a role for these adipocytokines in molecular linkage of obesity, Type 2 Diabetes mellitus and metabolic syndrome. Since then, it became apparent that the story of resistin and RELMs was very much of mice and men. The putative role of this adipokine family evolved from that of a conveyor of insulin resistance in rodents to instigator of inflammatory processes in humans. Structural dissimilarity, variance in distribution profiles and a lack of corroborating evidence for functional similarities separate the biological functions of resistin in humans from that of rodents. Although present in gross visceral fat deposits in humans, resistin is a component of inflammation, being released from infiltrating white blood cells of the sub-clinical chronic low grade inflammatory response accompanying obesity, rather than from the adipocyte itself. This led researchers to further explore the functions of the resistin family of proteins in inflammatory-related conditions such as atherosclerosis, as well as in cancers such as endometrial and gastric cancers. Although elevated levels of resistin have been found in these conditions, whether it is causative or as a result of these conditions still remains to be determined.

【 授权许可】

   
2015 Al Hannan and Culligan.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]WHO: Waist Circumference and Waist-Hip Ratio. WHO, Geneva; 2008.
• [2]Barnes AS: The epidemic of obesity and diabetes: trends and treatments. Tex Heart Inst J 2011, 38(2):142-4.
• [3]Waalen J: The genetics of human obesity. Transl Res 2014, 164(4):293-301.
• [4]Astrup A, Finer N: Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’? Obes Rev 2000, 1(2):57-9.
• [5]Björntorp P, Rosmond R: Visceral obesity and diabetes. Drugs 1999, 58(Suppl 1):13-8.
• [6]Chan DC, Watts GF: Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother 2011, 12(1):13-30.
• [7]Zhao J, Lawless MW: Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer. Cytokine 2013, 64(3):626-37.
• [8]Alexopoulos N, Katritsis D, Raggi P: Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis 2014, 233(1):104-12.
• [9]Mathieu P, Poirier P, Pibarot P, Lemieux I, Després JP: Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009, 53(4):577-84.
• [10]Seaquist ER: Microvascular complications of diabetes. Strategies for managing retinopathy, nephropathy, and neuropathy. Postgrad Med 1998, 103(1):61-3.
• [11]Cildir G, Akıncılar SC, Tergaonkar V: Chronic adipose tissue inflammation: all immune cells on the stage. Trends Mol Med 2013, 19(8):487-500.
• [12]Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo I: Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm 2013, 2013:136584.
• [13]Hauner H: Obesity and Diabetes. In Textbook of Diabetes. 4th edition. Edited by Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ. Wiley-Blackwell, Oxford; 2010:227-43.
• [14]Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006, 64(4):355-65.
• [15]Kennedy TJ, Kleh J, Bartol AB, Dickerson HC: The relationship between the clearance and the plasma concentration of inulin in normal man. J Clin Invest 1953, 32(1):90-5.
• [16]Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, PubMed eng(6505):425-32.
• [17]Trayhurn P, Beattie JH: Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001, 60(3):329-39.
• [18]Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, Matsubara K: Analysis of an expression profile of genes in the human adipose tissue. Gene 1997, 190(2):227-35.
• [19]Antuna-Puente B, Feve B, Fellahi S, Bastard JP: Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34(1):2-11.
• [20]Mraz M, Haluzik M: The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol 2014, 222(3):R113-27.
• [21]Rosenow A, Noben JP, Jocken J, Kallendrusch S, Fischer-Posovszky P, Mariman EC, et al.: Resveratrol-induced changes of the human adipocyte secretion profile. J Proteome Res 2012, 11(9):4733-43.
• [22]Makki K, Froguel P, Wolowczuk I: Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm 2013, 2013:139239.
• [23]Piya MK, McTernan PG, Kumar S: Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol 2013, 216(1):T1-T15.
• [24]Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270(45):26746-9.
• [25]Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11(2):85-97.
• [26]Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112(12):1796-808.
• [27]Gregor MF, Hotamisligil GS: Inflammatory mechanisms in obesity. Annu Rev Immunol 2011, 29:415-45.
• [28]Morris DL, Singer K, Lumeng CN: Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care 2011, 14(4):341-6.
• [29]Desvergne B: PPARdelta/beta: the lobbyist switching macrophage allegiance in favor of metabolism. Cell Metab 2008, 7(6):467-9.
• [30]Lumeng CN, Saltiel AR: Inflammatory links between obesity and metabolic disease. J Clin Invest 2011, 121(6):2111-7.
• [31]Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259(5091):87-91.
• [32]Fain JN: Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006, 74:443-77.
• [33]Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE: Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001, 9(7):414-7.
• [34]Waki H, Tontonoz P: Endocrine functions of adipose tissue. Annu Rev Pathol 2007, 2:31-56.
• [35]Chen G, Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science 2002, 296(5573):1634-5.
• [36]Tilg H, Moschen AR: Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008, 14(3–4):222-31.
• [37]Hivert MF, Sullivan LM, Fox CS, Nathan DM, D’Agostino RB, Wilson PW, et al.: Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008, 93(8):3165-72.
• [38]Fève B, Bastard JP: The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5(6):305-11.
• [39]Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-12.
• [40]Kim KH, Lee K, Moon YS, Sul HS: A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001, 276(14):11252-6.
• [41]Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al.: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000, 19(15):4046-55.
• [42]Ghosh S, Singh AK, Aruna B, Mukhopadhyay S, Ehtesham NZ: The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 2003, 305(1):27-34.
• [43]Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L: Disulfide-dependent multimeric assembly of resistin family hormones. Science. 2004, 304(5674):1154-8.
• [44]Eck MJ, Sprang SR: The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 1989, 264(29):17595-605.
• [45]Cuff ME, Miller KI, van Holde KE, Hendrickson WA: Crystal structure of a functional unit from Octopus hemocyanin. J Mol Biol 1998, 278(4):855-70.
• [46]Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G: The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A 2007, 104(37):14604-9.
• [47]Schwartz DR, Lazar MA: Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011, 22(7):259-65.
• [48]Steppan CM, Lazar MA: The current biology of resistin. J Intern Med 2004, 255(4):439-47.
• [49]Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al.: A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A 2001, 98(2):502-6.
• [50]Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al.: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300(2):472-6.
• [51]Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al.: Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003, 108(6):736-40.
• [52]Codoñer-Franch P, Alonso-Iglesias E: Resistin: Insulin resistance to malignancy. Clin Chim Acta 2014, 438C:46-54.
• [53]Raghu P, Ghosh S, Soundarya K, Haseeb A, Aruna B, Ehtesham NZ: Dimerization of human recombinant resistin involves covalent and noncovalent interactions. Biochem Biophys Res Commun 2004, 313(3):642-6.
• [54]Aruna B, Islam A, Ghosh S, Singh AK, Vijayalakshmi M, Ahmad F, et al.: Biophysical analyses of human resistin: oligomer formation suggests novel biological function. Biochemistry 2008, 47(47):12457-66.
• [55]Aruna B, Ghosh S, Singh AK, Mande SC, Srinivas V, Chauhan R, et al.: Human recombinant resistin protein displays a tendency to aggregate by forming intermolecular disulfide linkages. Biochemistry 2003, 42(36):10554-9.
• [56]Sánchez-Solana B, Laborda J, Baladrón V: Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol 2012, 26(1):110-27.
• [57]Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG: An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 2011, 9(1):74-86.
• [58]Banerjee RR, Lazar MA: Dimerization of resistin and resistin-like molecules is determined by a single cysteine. J Biol Chem 2001, 276(28):25970-3.
• [59]Renigunta A, Hild C, Rose F, Klepetko W, Grimminger F, Seeger W, et al.: Human RELMbeta is a mitogenic factor in lung cells and induced in hypoxia. FEBS Lett 2006, 580(3):900-3.
• [60]Mishra A, Wang M, Schlotman J, Nikolaidis NM, DeBrosse CW, Karow ML, et al.: Resistin-like molecule-beta is an allergen-induced cytokine with inflammatory and remodeling activity in the murine lung. Am J Physiol Lung Cell Mol Physiol 2007, 293(2):L305-13.
• [61]Fang C, Meng Q, Wu H, Eid G, Zhang G, Zhang X, et al.: Resistin-like molecule-β is a human airway remodelling mediator. Eur Respir J 2012, 39(2):458-66.
• [62]McVay LD, Keilbaugh SA, Wong TM, Kierstein S, Shin ME, Lehrke M, et al.: Absence of bacterially induced RELMbeta reduces injury in the dextran sodium sulfate model of colitis. J Clin Invest 2006, 116(11):2914-23.
• [63]Neilson AP, Djuric Z, Land S, Kato I: Plasma levels of resistin-like molecule beta in humans. Cancer Epidemiol 2011, 35(5):485-9.
• [64]Kushiyama A, Sakoda H, Oue N, Okubo M, Nakatsu Y, Ono H, et al.: Resistin-like molecule β is abundantly expressed in foam cells and is involved in atherosclerosis development. Arterioscler Thromb Vasc Biol 2013, 33(8):1986-93.
• [65]Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, et al.: Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol 2005, 77(3):321-7.
• [66]Gerstmayer B, Küsters D, Gebel S, Müller T, Van Miert E, Hofmann K, et al.: Identification of RELMgamma, a novel resistin-like molecule with a distinct expression pattern. Genomics 2003, 81(6):588-95.
• [67]Farag YM, Gaballa MR: Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. 2011, 26(1):28-35.
• [68]Colagiuri S: Diabesity: therapeutic options. Diabetes Obes Metab 2010, 12(6):463-73.
• [69]Arner P: Resistin: yet another adipokine tells us that men are not mice. Diabetologia 2005, 48(11):2203-5.
• [70]Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, et al.: Regulation of fasted blood glucose by resistin. Science 2004, 303(5661):1195-8.
• [71]Nagaev I, Smith U: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001, 285(2):561-4.
• [72]Jiang S, Park DW, Tadie JM, Gregoire M, Deshane J, Pittet JF, et al.: Human resistin promotes neutrophil proinflammatory activation and neutrophil extracellular trap formation and increases severity of acute lung injury. J Immunol 2014, 192(10):4795-803.
• [73]Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, et al.: Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun. 2003, 310(3):927-35.
• [74]Delhanty PJ, Mesotten D, McDougall F, Baxter RC: Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats. Endocrinology 2002, 143(6):2445-8.
• [75]Nogueiras R, Gualillo O, Caminos JE, Casanueva FF, Diéguez C: Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 2003, 11(3):408-14.
• [76]Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112(12):1821-30.
• [77]Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001, 288(4):1027-31.
• [78]Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA: An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004, 1(2):e45.
• [79]Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C, et al.: Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 2003, 310(2):641-5.
• [80]Nakata M, Okada T, Ozawa K, Yada T: Resistin induces insulin resistance in pancreatic islets to impair glucose-induced insulin release. Biochem Biophys Res Commun 2007, 353(4):1046-51.
• [81]Hsu WY, Chao YW, Tsai YL, Lien CC, Chang CF, Deng MC, et al.: Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. J Cell Physiol 2011, 226(8):2181-8.
• [82]Xu W, Yu L, Zhou W, Luo M: Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun 2006, 351(2):376-82.
• [83]Diakowska D, Markocka-Mączka K, Szelachowski P, Grabowski K: Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients. Dis Markers 2014, 2014:619649.
• [84]Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, et al.: Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009, 44(7):685-90.
• [85]Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al.: Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010, 101(5):1286-91.
• [86]Hlavna M, Kohut L, Lipkova J, Bienertova-Vasku J, Dostalova Z, Chovanec J, et al.: Relationship of resistin levels with endometrial cancer risk. Neoplasma 2011, 58(2):124-8.
• [87]Dalamaga M, Karmaniolas K, Papadavid E, Pelekanos N, Sotiropoulos G, Lekka A: Hyperresistinemia is associated with postmenopausal breast cancer. Menopause. 2013, 20(8):845-51.
• [88]Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al.: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004, 314(2):415-9.
• [89]Pal S, Bhattacharjee A, Ali A, Mandal NC, Mandal SC, Pal M: Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond). 2014, 11:23.
• [90]Hsieh YY, Shen CH, Huang WS, Chin CC, Kuo YH, Hsieh MC, et al. Resistin-induced stromal cell-derived factor-1 expression through Toll-like receptor 4 and activation of p38 MAPK/ NFκB signaling pathway in gastric cancer cells. J Biomed Sci. 2014;21. PubMed Pubmed Central PMCID: PMC4089564. eng.
• [91]Yadav A, Kumar B, Datta J, Teknos TN, Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 2011, 9(12):1658-67.
• [92]He W, Wang ML, Jiang HQ, Steppan CM, Shin ME, Thurnheer MC, et al.: Bacterial colonization leads to the colonic secretion of RELMbeta/FIZZ2, a novel goblet cell-specific protein. Gastroenterology 2003, 125(5):1388-97.
• [93]Zheng L, Weng M, He J, Yang X, Jiang G, Tong Q: Expression of resistin-like molecule beta in gastric cancer: its relationship with clinicopathological parameters and prognosis. Virchows Arch 2010, 456(1):53-63.
• [94]Zheng LD, Tong QS, Weng MX, He J, Lv Q, Pu JR, et al.: Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance. Dig Dis Sci 2009, 54(2):274-81.
• [95]Menzaghi C, Coco A, Salvemini L, Thompson R, De Cosmo S, Doria A, et al.: Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. J Clin Endocrinol Metab 2006, 91(7):2792-5.
• [96]Chi S, Lan C, Zhang S, Liu H, Wang X, Chen Y, et al.: Association of -394C > G and -420C > G polymorphisms in the RETN gene with T2DM and CHD and a new potential SNP might be exist in exon 3 of RETN gene in Chinese. Mol Cell Biochem 2009, 330(1–2):31-8.
• [97]Sentinelli F, Romeo S, Arca M, Filippi E, Leonetti F, Banchieri M, et al.: Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002, 51(3):860-2.
• [98]Wang H, Chu WS, Hemphill C, Elbein SC: Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002, 87(6):2520-4.
• [99]Ortega L, Riestra P, Navarro P, Gavela-Pérez T, Soriano-Guillén L, Garcés C: Resistin levels are related to fat mass, but not to body mass index in children. Peptides 2013, 49:49-52.
• [100]Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, et al.: Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des 2014, 20(31):4961-9.
• [101]Osawa H, Onuma H, Ochi M, Murakami A, Yamauchi J, Takasuka T, et al.: Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun 2005, 335(2):596-602.
• [102]Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, et al.: PPARgamma Pro12Ala Pro/Pro and resistin SNP-420 G/G genotypes are synergistically associated with plasma resistin in the Japanese general population. Clin Endocrinol (Oxf) 2009, 71(3):341-5.
• [103]Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, et al.: The G/G genotype of a resistin single-nucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 2004, 75(4):678-86.
• [104]Chung SS, Choi HH, Kim KW, Cho YM, Lee HK, Park KS: Regulation of human resistin gene expression in cell systems: an important role of stimulatory protein 1 interaction with a common promoter polymorphic site. Diabetologia 2005, 48(6):1150-8.
• [105]Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, et al.: Plasma resistin, associated with single nucleotide polymorphism −420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 2007, 30(6):1501-6.
• [106]Tsukahara T, Nakashima E, Watarai A, Hamada Y, Naruse K, Kamiya H, et al.: Polymorphism in resistin promoter region at −420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2009, 84(2):179-86.
• [107]El-Shal AS, Pasha HF, Rashad NM: Association of resistin gene polymorphisms with insulin resistance in Egyptian obese patients. Gene 2013, 515(1):233-8.
• [108]Hasegawa G, Ohta M, Ichida Y, Obayashi H, Shigeta M, Yamasaki M, et al.: Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetol 2005, 42(2):104-9.
• [109]Pfützner A, Langenfeld M, Kunt T, Löbig M, Forst T: Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 2003, 49(11–12):571-6.
• [110]Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004, 27(10):2450-7.
• [111]Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C: Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One 2014, 9(3):e91969.
• [112]Makni E, Moalla W, Benezzeddine-Boussaidi L, Lac G, Tabka Z, Elloumi M: Correlation of resistin with inflammatory and cardiometabolic markers in obese adolescents with and without metabolic syndrome. Obes Facts 2013, 6(4):393-404.
• [113]Stejskal D, Adamovská S, Bartek J, Juráková R, Prosková J: Resistin - concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003, 147(1):63-9.
• [114]Akagun T, Caliskan Y, Yazici H, Ozkok A, Telci A, Turkmen A, et al.: Elevated resistin levels are associated with inflammation in hemodialysis patients with failed renal allografts. Int J Artif Organs 2014, 37(5):358-63.
• [115]Menzaghi C, Bacci S, Salvemini L, Mendonca C, Palladino G, Fontana A, et al.: Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS One 2013, 8(6):e64729.
• [116]Hossein-Nezhad A, Varzaneh FN, Mirzaei K, Emamgholipour S, Sahraian MA: A polymorphism in the resistin gene promoter and the risk of multiple sclerosis. Minerva Med 2013, 104(4):431-8.
• [117]Dong XQ, Du Q, Yu WH, Zhang ZY, Zhu Q, Che ZH, et al.: Plasma resistin, associated with single nucleotide polymorphism −420, is correlated with C-reactive protein in Chinese Han patients with spontaneous basal ganglia hemorrhage. Genet Mol Res 2012, 11(3):1841-50.
• [118]Arama V, Munteanu DI, Streinu Cercel A, Ion DA, Mihailescu R, Tiliscan C, et al.: Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin. J Endocrinol Invest 2014, 37(6):533-9.
• [119]Słomian G, Świętochowska E, Malinowska-Borowska J, Kasperczyk S, Rogalska A, Nowak P: Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Rep 2014, 66(5):902-7.
• [120]Kang JH, Yu BY, Youn DS: Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 2007, 22(1):117-21.
• [121]Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, et al.: Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 2014, 19(3):484-97.
• [122]Hubberstey AV, Mottillo EP: Cyclase-associated proteins: CAPacity for linking signal transduction and actin polymerization. FASEB J 2002, 16(6):487-99.
• [123]Tarkowski A, Bjersing J, Shestakov A: Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010, 14(6B):1419-31.
• [124]Pirvulescu MM, Gan AM, Stan D, Simion V, Calin M, Butoi E, et al.: Subendothelial resistin enhances monocyte transmigration in a co-culture of human endothelial and smooth muscle cells by mechanisms involving fractalkine, MCP-1 and activation of TLR4 and Gi/o proteins signaling. Int J Biochem Cell Biol 2014, 50:29-37.
• [125]O’Reilly SM, Moynagh PN: Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. Biochem Biophys Res Commun 2003, 303(2):586-93.